TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22145698

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: linagliptin 10 mg
Number of subjects: 561

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 561

Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg, linagliptin 10 mg, placebo, voglibose
Number of subjects: 561
Study: 19280566

Group type: EXPERIMENTAL
Intervention: Executive function training for 3 years
Number of subjects: 25

Group type: COMPARATOR
Intervention: No executive function training (control group)
Number of subjects: 25
Study: 17719682

Group type: EXPERIMENTAL
Intervention: Needle-free valve connection system (NFVCS)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Three-way stopcock connection (3WSC)
Number of subjects: 799
Study: 14715975

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 615
Study: 11216952

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) on a bicycle ergometer for four weeks (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inactive control group (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) on a bicycle ergometer
Number of subjects: 22
Study: 9648963

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7865532

Group type: EXPERIMENTAL
Intervention: Obliterative bronchiolitis group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 2478779

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 177210

Group type: EXPERIMENTAL
Intervention: BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Previous combination of procarbazine, CCNU, and vincristine
Number of subjects: 65
Study: 31704429

Group type: EXPERIMENTAL
Intervention: Breath counting mindfulness training
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (popular science extract)
Number of subjects: 192
Study: 31135850

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1056
Study: 28625637

Group type: EXPERIMENTAL
Intervention: LY2603618 + Pemetrexed + Cisplatin (LY+Pem+Cis)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pemetrexed + Cisplatin (Pem+Cis)
Number of subjects: 62
Study: 25924819

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg four times daily (q.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg two times a day (b.i.d.)
Number of subjects: 30
Study: 23949918

Group type: EXPERIMENTAL
Intervention: add-on extended release nicotinic acid/laropiprant (ER-NA/LRPT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: add-on fenofibrate
Number of subjects: 100
Study: 21270789

Group type: EXPERIMENTAL
Intervention: Buprenorphine (B) 16 mg, n = 18
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (B/N) 16/4 mg, n = 16
Number of subjects: 34
Study: 18650507

Group type: EXPERIMENTAL
Intervention: 80 mg of simvastatin daily
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin daily
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not specified dosage)
Number of subjects: 175
Study: 15861064

Group type: EXPERIMENTAL
Intervention: Blake drain
Number of subjects: 43
Study: 12640070

Group type: EXPERIMENTAL
Intervention: Coeliac disease patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Reflux disease patients
Number of subjects: 49
Study: 10933183

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation (PBSCT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Bone Marrow Transplantation (BM)
Number of subjects: 74
Study: 8790926

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/triamterene
Number of subjects: 65
Study: 1729864

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 104
Study: 6429852

Group type: EXPERIMENTAL
Intervention: 30 mg 2% nitroglycerin ointment (Plantorgan Co.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 10 mg 2% nitroglycerin ointment (Pohl Boskamp Co.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 25 mg nitroglycerin in the transdermal therapeutic system (Ciba Geigy)
Number of subjects: 44
Study: 30910440

Group type: EXPERIMENTAL
Intervention: GSP301 (665 μg of olopatadine and 25 μg of mometasone)
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Olopatadine (665 μg)
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Mometasone (25 μg)
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1176
Study: 29974521

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg intravenous before graft reperfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) treatment
Number of subjects: 40
Study: 27763846

Group type: EXPERIMENTAL
Intervention: NFTs with calories in large font
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Traffic Light format with small font
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Current, RDI and Traffic Light formats with large font
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Infographic format
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Large font calorie condition
Number of subjects: 2008
Study: 25496425

Group type: EXPERIMENTAL
Intervention: Dementia-specific case conferences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23336412

Group type: EXPERIMENTAL
Intervention: Protein-free calf blood extract ophthalmic gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Recombinant bovine basic fibroblast growth factor ophthalmic gel
Number of subjects: 36
Study: 20198491

Group type: EXPERIMENTAL
Intervention: Gatekeeper Reflux Repair System (GK)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 204
Study: 19063816

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% ophthalmic solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluticasone furoate nasal spray
Number of subjects: 60
Study: 12764120

Group type: EXPERIMENTAL
Intervention: Verbal suggestions of analgesia/hyperalgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal suggestions of motor improvement/worsening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preconditioning with sumatriptan (5‐HT(1B/1D) agonist) followed by placebo administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal suggestions of increase/decrease of growth hormone (GH) and cortisol
Number of subjects: 0
Study: 10696854

Group type: EXPERIMENTAL
Intervention: Nasal challenge with NRL
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9327315

Group type: EXPERIMENTAL
Intervention: Midazolam + Oral Transmucosal Fentanyl Citrate (OTFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam + Placebo
Number of subjects: 0
Study: 8447743

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 256
Study: 3769604

Group type: EXPERIMENTAL
Intervention: Day-care program designed to prevent mild mental retardation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Educationally untreated control group
Number of subjects: 80
Study: 30982086

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 29456128

Group type: EXPERIMENTAL
Intervention: Active tDCS combined with CIMT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS combined with CIMT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Children with preserved corticospinal tract circuitry
Number of subjects: 20
Study: 26968024

Group type: EXPERIMENTAL
Intervention: Early goal‐directed mobilization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 25156854

Group type: EXPERIMENTAL
Intervention: Multi-electrode, phased radiofrequency ablation (MER group)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Conventional, point‐by‐point ablation with a radiofrequency ablation catheter (cPVI group)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Both groups (cPVI and MER)
Number of subjects: 460
Study: 22423099

Group type: EXPERIMENTAL
Intervention: Corticomuscular coherence during articulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticomuscular coherence
Number of subjects: 0
Study: 19955098

Group type: EXPERIMENTAL
Intervention: Cumulative diarrhoea occurrence over 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative diarrhoea occurrence over 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trial arms comparison
Number of subjects: 0
Study: 18157519

Group type: EXPERIMENTAL
Intervention: UDCA (300 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15753414

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg daily for 12 months)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 12616667

Group type: EXPERIMENTAL
Intervention: Nizatidine in apple juice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nizatidine in infant formula
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Commercially prepared oral syrup
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference capsule formulation
Number of subjects: 24
Study: 10546521

Group type: EXPERIMENTAL
Intervention: Tamoxifen and/or chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New cytotoxic drugs (taxanes, vinorelbine, capecitabine), high dose chemotherapy, immunotherapy with monoclonal antibodies (herceptin), gene therapeutic approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive factors and biological markers
Number of subjects: 0
Study: 8699547

Group type: EXPERIMENTAL
Intervention: Compulsory supervision group
Number of subjects: 610

Group type: COMPARATOR
Intervention: Voluntary group (no compulsory supervision)
Number of subjects: 610
Study: 2061529

Group type: EXPERIMENTAL
Intervention: Planned walking for 30 minutes three times a week for 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conversation for 30 minutes three times a week for 10 weeks
Number of subjects: 30
Study: 6406616

Group type: EXPERIMENTAL
Intervention: Cefazolin prophylaxis (5 doses of 1g)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Cefazolin prophylaxis
Number of subjects: 361
Study: 29737412

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1261
Study: 27522486

Group type: EXPERIMENTAL
Intervention: Speedinc (baseline pump speed + 800 rpm)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Speedbase (fixed baseline pump speed)
Number of subjects: 19
Study: 26761562

Group type: EXPERIMENTAL
Intervention: Interactive video-game group intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional group intervention
Number of subjects: 39
Study: 24333554

Group type: EXPERIMENTAL
Intervention: Rg3-loaded PLGA electrospun fibrous membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 0
Study: 23091128

Group type: COMPARATOR
Intervention: Group F: heat‐inactivated Lactobacillus salivarius and Bacillus subtilis
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Group G: inactivated Lactobacillus salivarius and sodium butyrate
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups D and H
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups B, H, and I
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups D, E, and G
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups E and G
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups B, C, E, G, and I after d 15
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups B, C, D, E, F, G, and H after d 45
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Groups F and G at d 45
Number of subjects: 1800
Study: 19114683

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX‐4 (n = 169)
Number of subjects: 337

Group type: COMPARATOR
Intervention: FOLFOX‐4 alone (n = 168)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX‐4 in KRAS wild-type tumors
Number of subjects: 337

Group type: COMPARATOR
Intervention: FOLFOX‐4 alone in KRAS wild-type tumors
Number of subjects: 337
Study: 17968180

Group type: EXPERIMENTAL
Intervention: Iloprost in saline solution for 3 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 98
Study: 14767293

Group type: EXPERIMENTAL
Intervention: Behavioral modification program (BMP)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 359
Study: 11719297

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 44
Study: 9425969

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 3.4 mL of hypobaric 0.18% bupivacaine (6.12 mg)
Number of subjects: 70
Study: 8483561

Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: FEM (5-fluorouracil 600 mg/m2, epirubicin 50 mg/m2, mitomycin 6 mg/m2)
Number of subjects: 60
Study: 2961394

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sclerosants
Number of subjects: 0
Study: 30545409

Group type: EXPERIMENTAL
Intervention: Intensive external facilitation implementation intervention to increase OAT prescribing rates
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control sites (not specified in detail)
Number of subjects: 8
Study: 26791805

Group type: EXPERIMENTAL
Intervention: Testofen (Trigonella foenum-graecum seed extract) at a dose of 600 mg/day for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24257810

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23216401

Group type: EXPERIMENTAL
Intervention: Short-term individual dynamic therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (augmented treatment)
Number of subjects: 100
Study: 20507973

Group type: EXPERIMENTAL
Intervention: Aged group at rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aged group during exercise
Number of subjects: 12
Study: 18179314

Group type: EXPERIMENTAL
Intervention: Neurofeedback-induced decrease in relative left frontal cortical activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action-oriented mindset manipulation
Number of subjects: 0
Study: 15933528

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel) added to tonsillar fossa during tonsillectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional complete tonsillectomy without fibrin sealant
Number of subjects: 40
Study: 12589986

Group type: EXPERIMENTAL
Intervention: CPR plus use of an AED
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CPR alone
Number of subjects: 1000
Study: 12814316

Group type: EXPERIMENTAL
Intervention: HA-coated threaded implants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HA-coated cylindric implants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: machined Ti threaded implants
Number of subjects: 120
Study: 9780560

Group type: EXPERIMENTAL
Intervention: Antiandrogen therapy combined with radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study: 7624193

Group type: EXPERIMENTAL
Intervention: Inconsistent picture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consistent picture
Number of subjects: 0
Study: 2529333

Group type: EXPERIMENTAL
Intervention: Ultrasound-directed oocyte pickup (OPU)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Laparoscopic oocyte pickup (OPU)
Number of subjects: 94
Study: 16622

Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 20
Study: 31843827

Group type: EXPERIMENTAL
Intervention: Health insurance coverage (at least one member covered)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unemployment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Seeking care from a public health facility
Number of subjects: 300

Group type: COMPARATOR
Intervention: Perceived health status as good
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unsatisfied with the cost of seeking primary care
Number of subjects: 300
Study: 28170391

Group type: EXPERIMENTAL
Intervention: Higher dose of primaquine (1 mg base/kg/day for 7 days)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Standard high dose of primaquine (0.5 mg base/kg/day for 14 days)
Number of subjects: 241
Study: 26432125

Group type: EXPERIMENTAL
Intervention: Partial coherence interferometry (PCI) measurements with ACMaster device
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Optical low-coherence reflectometry (OLCR) measurements with Lenstar LS900 device
Number of subjects: 65

Group type: COMPARATOR
Intervention: Comparison of PCI and OLCR measurements
Number of subjects: 65
Study: 23859649

Group type: EXPERIMENTAL
Intervention: Higher endogenous testosterone levels in boys
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Higher endogenous testosterone levels in girls
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Smaller medial OFC volume in boys
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Larger OFC surface area in girls
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: OFC morphology
Number of subjects: 268
Study: 21616170

Group type: EXPERIMENTAL
Intervention: 30 g of milled flaxseed per day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 19230757

Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16765760

Group type: EXPERIMENTAL
Intervention: Repeat intramuscular dose of 11.4 mg betamethasone (as Celestone Chronodose)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 982
Study: 14757602

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine (0.9 mg/kg of 2.25% racemic epinephrine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nebulized albuterol (0.15 mg/kg of 0.5% albuterol sulfate)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nebulized albuterol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study: 11710391

Group type: EXPERIMENTAL
Intervention: LBNP group, received -4.0 kPa LBNP training 1 h/d in the last week of the test
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group, exposed to -6 degrees HDT for 21 days without LBNP training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (LBNP and Control) during HDT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (LBNP and Control) post HDT
Number of subjects: 12
Study: 9437950

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 101

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 8497648

Group type: EXPERIMENTAL
Intervention: Tangential fluoroscopic guidance (group A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No tangential fluoroscopic guidance (group B)
Number of subjects: 92
Study: 2963230

Group type: EXPERIMENTAL
Intervention: High-dose leucovorin plus FUra (Arm B)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate, FUra, leucovorin (Arm C)
Number of subjects: 102
Study: 31314564

Group type: EXPERIMENTAL
Intervention: ACT group intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study: 28049559

Group type: EXPERIMENTAL
Intervention: Image-interpretive task workflow
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Non-image interpretive task workflow
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Image interpretation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Non-image interpretive tasks (phone calls/paging)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Non-image interpretive tasks (in-room consultations)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Non-image interpretive tasks (protocoling)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Consult assistant (CA)
Number of subjects: 1
Study: 25830947

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19) 10(8) CFU
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (cereals without LF19)
Number of subjects: 179
Study: 22820873

Group type: EXPERIMENTAL
Intervention: Tuning into Kids (TIK) parenting program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist (clinical treatment as usual)
Number of subjects: 54
Study: 21853859

Group type: EXPERIMENTAL
Intervention: Amino acid-carbohydrate (AACHO) prior to resistance exercise (979 kJ, 36 g carbohydrate, 22.5 g protein)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PLAC) prior to resistance exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AACHO and PLAC (pooled)
Number of subjects: 6
Study: 18820657

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 20 mg triamcinolone acetonide with topical 1% prednisolone acetate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous injection of 500 mg methylprednisolone with topical 1% prednisolone acetate
Number of subjects: 32